The targeted drug Herceptin, containing the humanizedmonoclonal antibody (mAb) trastuzumab, which the first compound capable ofsuppressing HER2/neu function approved by the FDA (Food and DrugAdministration, USA) in 1998, remains the gold standard in the treatment ofHER2- positive BC. The gene discussed is ERBB2; the disease is breast cancer.